IRISYS Chairman, CEO & Founder Represents Biotech Industry at San Diego US-China Trade Relations Meeting

Dr. Jerry Yakatan, Chairman, CEO & Founder of IRISYS, was honored to be the biotechnology industry representative at the invitation-only US-China Trade Relations Meeting –


San Diego, July 19, 2018 – Dr. Jerry Yakatan, Chairman, CEO & Founder of IRISYS, was honored to be the biotechnology industry representative at the invitation-only US-China Trade Relations Meeting hosted by the World Trade Center San Diego / San Diego Regional EDC on July 16, 2018. The meeting was an interactive session with Alan Turley, Deputy Assistant Secretary of Commerce for China and Mongolia in the U.S. Department of Commerce’s International Trade Administration.

Dr. Yakatan was a selected guest of the San Diego Department of Commerce / US Commercial Services. He was invited to be of help by providing his perspective on doing business in China. He gave comments and responded to questions from Mr. Turley and the other participants.

Alan Turley leads a team of over 160 professionals in the U.S. and overseas. He advises the leadership in the Department of Commerce on trade-policy issues regarding the commercial relationship between the U.S. and China and helps shape the Department’s trade promotion agenda.

IRISYS has long-standing relationships with pharmaceutical companies in China that use our international services to help take their new drug candidates through the U.S. FDA regulatory process. Dr. Yakatan described our work with Chinese and other companies that need strategic planning and regulatory guidance from IRISYS to advance their products from R&D and early preclinical stages to clinical trials and FDA approval.

Dr. Yakatan also discussed IRISYS’ new memorandum of understanding for a joint venture with Zhejiang Yangtse River Delta Biotech Management to co-build and co-run a new Drug Delivery Systems platform as a key part of the International Accelerator in Hangzhou, Zehjiang province, China.  He explained that establishing a Drug Delivery Systems platform in Zehjiang province will allow IRISYS to address the needs of Chinese pharmaceutical companies directly, serving them from a local base.  It will also enable IRISYS to assist U.S. pharma and biotechnology companies interested in entering the Chinese market.

Biotech and pharmaceutical company representatives interested in doing in China or speaking with Dr. Yakatan are welcome to submit the IRISYS contact form.

About IRISYS (irisys.com)

IRISYS was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and strategic consulting related to the drug development process. IRISYS’ custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving more than 100 drug products from discovery to clinical development and commercialization

IRISYS Contacts

Louis Scotti
Vice President Business Development
+1-858-281-7943
lscotti@irisys.com

Gwen Rosenberg
Rosenberg Business Communications
+1-858-525-5484
gwen@rosenbergbc.com